These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 12881371)

  • 21. 17-AAG: mechanisms of antitumour activity.
    Konstantinopoulos PA; Papavassiliou AG
    Expert Opin Investig Drugs; 2005 Dec; 14(12):1471-4. PubMed ID: 16307487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic and diagnostic implications of Hsp90 activation.
    Kamal A; Boehm MF; Burrows FJ
    Trends Mol Med; 2004 Jun; 10(6):283-90. PubMed ID: 15177193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.
    Zhang H; Yang YC; Zhang L; Fan J; Chung D; Choi D; Grecko R; Timony G; Karjian P; Boehm M; Burrows F
    Int J Cancer; 2007 Feb; 120(4):918-26. PubMed ID: 17131314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered states: selectively drugging the Hsp90 cancer chaperone.
    Workman P
    Trends Mol Med; 2004 Feb; 10(2):47-51. PubMed ID: 15106614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
    Yin X; Zhang H; Burrows F; Zhang L; Shores CG
    Clin Cancer Res; 2005 May; 11(10):3889-96. PubMed ID: 15897590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts.
    Nimmanapalli R; O'Bryan E; Bhalla K
    Cancer Res; 2001 Mar; 61(5):1799-804. PubMed ID: 11280726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.
    Münster PN; Basso A; Solit D; Norton L; Rosen N
    Clin Cancer Res; 2001 Aug; 7(8):2228-36. PubMed ID: 11489796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
    Kaur G; Belotti D; Burger AM; Fisher-Nielson K; Borsotti P; Riccardi E; Thillainathan J; Hollingshead M; Sausville EA; Giavazzi R
    Clin Cancer Res; 2004 Jul; 10(14):4813-21. PubMed ID: 15269157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heat shock protein and proteasome targeting agents.
    Takimoto CH; Diggikar S
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1269-85. PubMed ID: 12512392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
    Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
    Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
    Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
    Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
    Miyata Y
    Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types.
    Gossett DR; Bradley MS; Jin X; Lin J
    Gynecol Oncol; 2005 Feb; 96(2):381-8. PubMed ID: 15661225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 17-Allylamino-17-demethoxygeldanamycin and Herbimycin A Induce Cell Death by Modulating β-Catenin and PI3K/AKT Signaling in FRO Anaplastic Thyroid Carcinoma Cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Anticancer Res; 2015 Oct; 35(10):5453-60. PubMed ID: 26408708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.
    Münster PN; Srethapakdi M; Moasser MM; Rosen N
    Cancer Res; 2001 Apr; 61(7):2945-52. PubMed ID: 11306472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
    Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG.
    Ivy PS; Schoenfeldt M
    Oncology (Williston Park); 2004 May; 18(5):610, 615, 619-20. PubMed ID: 15209189
    [No Abstract]   [Full Text] [Related]  

  • 40. Identification of new biomarkers for clinical trials of Hsp90 inhibitors.
    Zhang H; Chung D; Yang YC; Neely L; Tsurumoto S; Fan J; Zhang L; Biamonte M; Brekken J; Lundgren K; Burrows F
    Mol Cancer Ther; 2006 May; 5(5):1256-64. PubMed ID: 16731758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.